Rice Hall James & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Rice Hall James & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,850	Closed	-$393K	–	312
2016 Q4	$393K	Hold	10,850	–	–	0.02%	273
2016 Q3	$499K	Hold	10,850	–	–	0.03%	255
2016 Q2	$545K	Sell	10,850 -300	-3%	-$16K	0.03%	254
2016 Q1	$597K	Hold	11,150	–	–	0.03%	247
2015 Q4	$732K	Hold	11,150	–	–	0.04%	247
2015 Q3	$630K	Hold	11,150	–	–	0.04%	256
2015 Q2	$659K	Hold	11,150	–	–	0.04%	259
2015 Q1	$695K	Hold	11,150	–	–	0.04%	262
2014 Q4	$641K	Hold	11,150	–	–	0.04%	260
2014 Q3	$599K	Hold	11,150	–	–	0.04%	252
2014 Q2	$584K	Sell	11,150 -200	-2%	-$10.2K	0.04%	260
2014 Q1	$600K	Hold	11,350	–	–	0.04%	252
2013 Q4	$455K	Buy	11,350 +400	+4%	+$15.8K	0.03%	262
2013 Q3	$414K	Hold	10,950	–	–	0.04%	240
2013 Q2	$429K	Buy	+10,950	New	+$426K	0.04%	230

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Rice Hall James & Associates's TEVA Position: Q1 2017 in Review

Rice Hall James & Associates sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 10,850 shares — an estimated $393K sold.

Rice Hall James & Associates first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $732K in Q4 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Rice Hall James & Associates reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Rice Hall James & Associates sold 10,850 Teva Pharmaceuticals shares in Q1 2017, an estimated $393K.
Rice Hall James & Associates first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Rice Hall James & Associates's Teva Pharmaceuticals position peaked at $732K in Q4 2015.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Rice Hall James & Associates's 13F filing for Q1 2017, filed 19 Apr 2017.